Detalhe da pesquisa
1.
A Phase 1 Study To Evaluate Safety and Pharmacokinetics following Administration of Single and Multiple Doses of the Antistaphylococcal Lysin LSVT-1701 in Healthy Adult Subjects.
Antimicrob Agents Chemother
; 66(3): e0184221, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35007129
2.
Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.
Antimicrob Agents Chemother
; 58(11): 6704-9, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25155600
3.
Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects.
Drug Metab Dispos
; 39(9): 1734-46, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21646437
4.
Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
Br J Clin Pharmacol
; 72(2): 321-9, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21434975
5.
Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants.
HIV Res Clin Pract
; 23(1): 1-8, 2021 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35285786
6.
Erratum for Wire et al., Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.
Antimicrob Agents Chemother
; 59(5): 2969, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25862822
7.
Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial.
HIV Clin Trials
; 11(5): 239-47, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-21126954
8.
Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects.
Br J Clin Pharmacol
; 70(1): 24-33, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20642544
9.
Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment.
Antimicrob Agents Chemother
; 53(12): 5185-96, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19667283
10.
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
J Antimicrob Chemother
; 64(2): 398-410, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19515730
11.
Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
Pharmacotherapy
; 28(7): 863-74, 2008 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-18576901
12.
Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
Clin Pharmacokinet
; 45(2): 137-68, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-16485915
13.
Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers.
AIDS
; 18(6): 897-907, 2004 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-15060437
14.
A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients.
Clin Infect Dis
; 39(4): 591-4, 2004 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15356829
15.
Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects.
Pharmacotherapy
; 24(9): 1110-21, 2004 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-15460171
16.
Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients.
J Clin Pharmacol
; 54(2): 206-14, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25272370
17.
Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data.
Pediatr Infect Dis J
; 33(1): 57-62, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23811743
18.
Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.
Pediatr Infect Dis J
; 33(1): 50-6, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23811744
19.
A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS.
Clin Ther
; 34(3): 699-709, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22336488
20.
Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.
J Clin Pharmacol
; 51(3): 301-8, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20418510